LISTING OF CLAIMS

Claims 1-75 (Canceled).

76. (Amended) A compound of the formula Ib



(Ib)

or a pharmaceutically acceptable salt or solvate thereof, wherein

either (i) R^1 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -NR^5CO-(C_1-C_6 alkylene)-OR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -OR^8, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^8R^9, -NR^5COR^5, -NR^5COR^6, -NR^5COR^8, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6 and

R^2 is -Y-Z,

or, R^1 and R^2, when taken together, represent unbranched C_3-C_4 alkylene, optionally wherein one methylene group of said C_3-C_4 alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R^5 or R^8,

and R^3 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, -CN, halo, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6,

or (ii) R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), and R^2 is H,

provided that

(a) for definition (i), R^1 and R^3 are not both H,

(b) for definition (i), R^1 and R^3 are not both optionally substituted phenyl, as defined therein,

(c) for definition (i), when R^1 and R^3 are both methyl, R^2 is not phenyl or methyl, and

(d) for definition (ii), R^1 and R^3 are not both methyl;

Y is a direct bond or C_1-C_3 alkylene;

Z is R^{10} or, where Y is [[C_1-C_3]] C_1-C_6 alkylene, Z is $-NR^5COR^{10}$, $-NR^5CONR^5R^{10}$, $-NR^5CONR^5COR^{10}$ or $-NR^5SO_2R^{10}$;

R^4 is dichloro-substituted phenyl;

each R^5 is independently either H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl, or, when two such groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent ~~azetidinyl, pyrrolidinyl,~~ piperidinyl~~, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl,~~ said ~~azetidinyl, pyrrolidinyl,~~ piperidinyl~~, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl~~ being optionally substituted by C_1-C_6 alkyl or C_3-C_7 cycloalkyl ~~and said piperazinyl and homopiperazinyl being optionally substituted on the nitrogen atom not taken together with the two R^5 groups to form the ring by $-COR^7$ or $-SO_2R^7$~~;

R^6 is a four to six-membered, aromatic, partially unsaturated or saturated non-heterocyclic group ~~containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s)~~, said non-heterocyclic group being optionally substituted by $-OR^5$, $-NR^5R^5$, -CN, oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, $-COR^7$ or halo;

R^7 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl;

R^8 is C_1-C_6 alkyl substituted by phenyl or pyridyl, said phenyl and pyridyl being optionally substituted by halo, -CN, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^7$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro-(C_1-C_6)-alkyl, C_3-C_7 cycloalkyl or C_1-C_6 alkoxy;

R^9 is H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl, said C_1-C_6 alkyl and C_3-C_7 cycloalkyl being optionally substituted by $-OR^5$, $-NR^5R^5$, $-NR^5COR^5$, $-CONR^5R^5$ or R^6;

R^{10} is (a) benzyl or C-linked R^6, said benzyl being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$,

$-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6, or (b) when R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), R^{10} is phenyl, C_1-C_6 alkyl or C_3-C_7 cycloalkyl each being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6;

X is $-CH_2-$, $-CHR^{11}-$, -CO-, -S-, -SO- or $-SO_2-$;

R^{11} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl or C_1-C_6 alkoxy; and

R^{12} is C_1-C_6 alkyl substituted by R^6, $-OR^5$, $-CONR^5R^5$, $-NR^5COR^5$ or $-NR^5R^5$.

77. (Previously presented) A compound according to claim 76 wherein R^1 is C_1-C_6 alkyl, $-OR^7$, $-CO_2R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^5CO$-(C_1-C_6 alkylene)-OR^5 or R^6, said C_1-C_6 alkyl being optionally substituted by halo, -CN, $-OR^5$, $-OR^8$, $-CO_2R^5$, $-CONR^5R^5$, $-OCONR^5R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^8R^9$, $-NR^5COR^5$, $-NR^5COR^6$, $-NR^5COR^8$, $-SO_2NR^5R^5$, $-NR^5CONR^5R^5$, $-NR^5SO_2R^7$ or R^6.

78. (Previously presented) A compound according to claim 77 wherein R^1 is C_1-C_6 alkyl, $-OR^7$, $-CO_2R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^5CO$-(C_1-C_6 alkylene)-OR^5 or R^6, said C_1-C_6 alkyl being optionally substituted by halo or $-OR^5$.

79. (Previously presented) A compound according to claim 78 wherein R^1 is C_1-C_3 alkyl, $-OCH_3$, $-CO_2$(C_1-C_2 alkyl), $-NHCO_2$(C_1-C_2 alkyl), $-NH_2$, $-N(CH_3)_2$, $-NHCOCH_2OCH_3$ or furanyl, said C_1-C_3 alkyl being optionally substituted by fluoro or -OH.

80. (Previously presented) A compound according to claim 79 wherein R^1 is methyl, ethyl, prop-2-yl, hydroxymethyl, trifluoromethyl, $-OCH_3$, $-CO_2CH_2CH_3$, $-NHCO_2CH_2CH_3$, $-NH_2$, $-N(CH_3)_2$, $-NHCOCH_2OCH_3$ or furan-2-yl.

81. (Previously presented) A compound according to claim 80 wherein R^1 is ethyl.

82. (Previously presented) A compound according to claim 76 wherein R^1 is methyl, ethyl, trifluoromethyl or $-CH_2NHCH_2$(4-cyanophenyl).

83. (Previously presented) A compound according to claim 76 wherein R^2 is H, C_1-C_6 alkyl, -(C_1-C_3 alkylene)-NR^5CO-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5CO-(phenyl), -(C_1-C_3 alkylene)-NR^5SO_2(C-linked R^6), -(C_1-C_3 alkylene)-NR^5CO(C-linked R^6), -(C_1-C_3 alkylene)-NR^5CO-(phenyl), each C_1-C_6 alkyl and phenyl being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6.

84. (Previously presented) A compound according to claim 83 wherein R^2 is H, C_1-C_6 alkyl, -(C_1-C_3 alkylene)-NR^5CO-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5CO-(phenyl), -(C_1-C_3 alkylene)-$NR^5SO_2R^6$, -(C_1-C_3 alkylene)-NR^5COR^6, -(C_1-C_3 alkylene)-NR^5CO-(phenyl), each C_1-C_6 alkyl and phenyl being optionally substituted by halo, $-OR^5$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$ or R^6.

85. (Previously presented) A compound according to claim 84 wherein R^2 is H, C_1-C_3 alkyl, -(C_1-C_2 alkylene)-NHCO-(C_1-C_3 alkyl), -(C_1-C_2 alkylene)-NHCONH-(C_1-C_3 alkyl), -(C_1-C_2 alkylene)-NHCONHCO-(phenyl), -(C_1-C_2 alkylene)-$NHSO_2R^6$, -(C_1-C_2 alkylene)-$NHCOR^6$, -(C_1-C_2 alkylene)-NHCO-(phenyl), each C_1-C_3 alkyl and phenyl being optionally substituted by fluoro, -OH, -O(C_1-C_6 alkyl), -CN, -CO_2(C_1-C_6 alkyl), $-CONH_2$, $-OCONH_2$, $-OCONHCO_2Ph$, $-NH_2$, -N(C_1-C_6 alkyl)$_2$, $-NHCONH_2$, $-NHCOCONH_2$ or R^6.

86. (Previously presented) A compound according to claim 83 wherein R^6 is 2,4-dihydroxypyrimidinyl, 1-methylimidazolyl, tetrahydrofuranyl, 1,5-dimethylpyrazolyl,

tetrazolyl, pyridinyl, pyrimidinyl, 3-hydroxypyridazinyl, 2-hydroxypyridinyl, 2-oxo-2H-pyranyl or 1,2,3-thiadiazolyl.

87. (Previously presented) A compound according to claim 85 wherein R^2 is H, -CH_2OH, -CH_2CH_2OH, -$CH_2CH_2CH_2OH$, -CH_2OCONH_2, -$CH_2CH_2OCONH_2$, -$CH_2OCONHCO_2Ph$, -$CH_2CO_2CH_2CH_3$, -$CH_2CH_2CO_2CH_3$, -$CH_2CH_2CO_2CH_2CH_3$, -$CH_2CH_2CONH_2$, -$CH_2CH_2NH_2$, -$CH_2CH_2CH_2NH_2$, -$CH_2CH_2NHCOCHF_2$, -$CH_2CH_2NHCOCH_2CN$, -$CH_2CH_2NHCOCH_2N(CH_3)_2$, -$CH_2CH_2NHCOCH_2OCH_3$, -$CH_2CH_2NHCOCH_2OH$, -$CH_2CH_2NHCOCH_2OCH_2CH_3$, -$CH_2CH_2NHCOCH_2NHCONH_2$, -$CH_2CH_2NHCOCONH_2$, -$CH_2CH_2NHCONHCH_2CH_2CH_3$, -$CH_2CH_2NHCONHCOPh$, -$CH_2CH_2NHCONHCO$(2,6-difluorophenyl), -$CH_2CH_2NHSO_2$(2,4-dihydroxypyrimidin-5-yl), -$CH_2CH_2NHSO_2$(1-methylimidazol-4-yl), -CH_2CH_2NHCO(tetrahydrofuran-2-yl), -CH_2CH_2NHCO(1,5-dimethylpyrazol-3-yl), -$CH_2CH_2NHCOCH_2$(tetrazol-1-yl), -$CH_2CH_2NHCOPh$, -CH_2CH_2NHCO(pyridin-2-yl), -CH_2CH_2NHCO(pyrimidin-2-yl), -CH_2CH_2NHCO(2-fluorophenyl), -CH_2CH_2NHCO(3-hydroxyphenyl), -CH_2CH_2NHCO(3-hydroxypyridazin-6-yl), -CH_2CH_2NHCO(2-hydroxypyridin-6-yl), -CH_2CH_2NHCO(2-oxo-2H-pyran-5-yl) or -CH_2CH_2NHCO(1,2,3-thiadiazol-4-yl).

88. (Previously presented) A compound according to claim 76 wherein R^2 is H, methyl, -CH_2CH_2OH, -$CH_2CH_2CH_2OH$, -$CH_2CH_2NH_2$, -$CH_2CH_2CH_2NH_2$, -CH_2CN, -$CH_2CH_2OCH_3$, -CH_2CONH_2, -$CH_2CH_2NHCOCH_2OCH_3$ or azetidin-3-yl.

89. (Previously presented) A compound according to claim 88 wherein R^2 is -CH_2CH_2OH, -$CH_2CH_2NH_2$, -CH_2CN or azetidin-3-yl.

90. (Previously presented) A compound according to claim 76 wherein R^3 is C_1-C_6 alkyl, -CO_2R^5, -$CONR^5R^5$, -$NR^5CO_2R^7$ or -NR^5R^5, said C_1-C_6 alkyl being optionally substituted by halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6.

91. (Previously presented) A compound according to claim 90 wherein R^3 is C_1-C_6 alkyl, $-CO_2R^5$, $-CONR^5R^5$, $-NR^5CO_2R^7$ or $-NR^5R^5$, said C_1-C_6 alkyl being optionally substituted by halo, CN or $-OR^5$.

92. (Previously presented) A compound according to claim 91 wherein R^3 is C_1-C_3 alkyl, $-CO_2(C_1$-C_2 alkyl), $-CONH_2$, $-NHCO_2(C_1$-C_4 alkyl), $-N(CH_3)_2$ or $-NH_2$, said C_1-C_3 alkyl being optionally substituted by halo, -CN or -OH.

93. (Previously presented) A compound according to claim 92 wherein R^3 is methyl, ethyl, prop-2-yl, hydroxymethyl, cyanomethyl, trifluoromethyl, $-CO_2CH_2CH_3$, $-CONH_2$, $-NHCO_2C(CH_3)_3$, $-N(CH_3)_2$ or $-NH_2$.

94. (Previously presented) A compound according to claim 93 wherein R^3 is methyl, ethyl, prop-2-yl or trifluoromethyl.

95. (Previously presented) A compound according to claim 94 wherein R^3 is ethyl.

Claims 96-98 (Canceled).

99. (Previously presented) A compound according to claim 76 wherein R^4 is 3,5-dichlorophenyl.

Claim 100 (Canceled).

101. (Previously presented) A compound according to claim 76 wherein X is $-CH_2$-, $-CHR^{11}$-, -CO-, -S- or $-SO_2$-.

102. (Previously presented) A compound according to claim 101 wherein X is $-CH_2-$, $-CH(OCH_3)-$, -CO-, -S- or $-SO_2-$.

103. (Previously presented) A compound according to claim 102 wherein X is $-CH_2-$ or -S-.

104. (Previously presented) A pharmaceutical composition comprising a compound of claim 76 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, diluent or carrier.

Claims 105-150 (Canceled).

151. (Previously presented) A compound selected from the group consisting of: 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-isopropyl-3-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate;

N^1-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}ethanediamide;

2-[(aminocarbonyl)amino]-*N*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}acetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-ethoxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-methoxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-3-hydroxybenzamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-hydroxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-(dimethylamino)acetamide;

2-cyano-*N*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}acetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-fluorobenzamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N'*-propylurea;

N-benzoyl-*N'*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}urea;

2-[4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazol-1-yl]acetate;

ethyl [4-(3,5-dichlorobenzyl)-5-isopropyl-3-methyl-1*H*-pyrazol-1-yl]acetate;

4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazole;

2-[4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazole;

2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol;

2-{4-[(3,5-dichlorophenyl)sulfonyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol;

4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazole;

2-[4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanamine;

2-[4-(3,5-dichlorobenzyl)-5-ethyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-ethyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-ethyl-3-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-ethyl-5-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-(dimethylamino)-5-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-methoxy-3-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-(2-furyl)-3-methyl-1*H*-pyrazol-1-yl]ethanol;

(3,5-dichlorophenyl)[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]methanone;

(±)-2-{4-[(3,5-dichlorophenyl)(methoxy)methyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol;

2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl carbamate;

methyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanoate;

ethyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanoate;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanamide;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]-1-propanol;

[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]methanol;

[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl carbamate;

2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanamine;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}benzamide;

2-[4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-3-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]-1-propanamine;

2-[4-[(3,5-dichlorophenyl)sulfanyl]-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2,2-difluoroacetamide;

ethyl 4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1*H*-pyrazole-3-carboxylate;

[4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-3-yl]acetonitrile;

[4-[(3,5-dichlorophenyl)sulfonyl]-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-3-yl]acetonitrile;

2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol;

4-(3,5-dichlorobenzyl)-3-ethyl-1*H*-pyrazol-5-amine;

ethyl 4-(3,5-dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-5-ylcarbamate;

N-[4-(3,5-dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-5-yl]-2-methoxyacetamide;

2-[4-(3,5-dichlorobenzyl)-5-(dimethylamino)-3-ethyl-1*H*-pyrazol-1-yl]ethanol;

ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazole-3-carboxylate;

ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazole-5-carboxylate;

2-[3-amino-4-(3,5-dichlorobenzyl)-5-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-5-methoxy-3-methyl-1*H*-pyrazol-1-yl]acetate;

2-[5-amino-4-(3,5-dichlorobenzyl)-3-ethyl-1*H*-pyrazol-1-yl]ethanol;

and the pharmaceutically acceptable salts and solvates thereof.

152. (Previously presented) The compound of claim 151, wherein said compound is selected from the group consisting of 2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol; 2-[4-[(3,5-dichlorophenyl)sulfanyl]-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol; and 2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol.

153. (Withdrawn) A method for the treatment of a human immunodeficiency viral (HIV), or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS) comprising the administration of an effective amount of a compound of the formula Ib



(Ib)

or a pharmaceutically acceptable salt or solvate thereof, wherein

either (i) R^1 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -NR^5CO-(C_1-C_6 alkylene)-OR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -OR^8, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^8R^9, -NR^5COR^5, -NR^5COR^6, -NR^5COR^8, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6 and

R^2 is -Y-Z,

or, R^1 and R^2, when taken together, represent unbranched C_3-C_4 alkylene, optionally wherein one methylene group of said C_3-C_4 alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R^5 or R^8,

and R^3 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, -CN, halo, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by

halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6,

or (ii) R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), and R^2 is H,

provided that

(a) for definition (i), R^1 and R^3 are not both H,

(b) for definition (i), R^1 and R^3 are not both optionally substituted phenyl, as defined therein,

(c) for definition (i), when R^1 and R^3 are both methyl, R^2 is not phenyl or methyl, and

(d) for definition (ii), R^1 and R^3 are not both methyl;

Y is a direct bond or [[C_1-C_3]] C_1-C_6 alkylene;

Z is R^{10} or, where Y is C_1-C_3 alkylene, Z is -NR^5COR^{10}, -$NR^5CONR^5R^{10}$, -$NR^5CONR^5COR^{10}$ or -$NR^5SO_2R^{10}$;

R^4 is phenyl or pyridyl, each substituted by at least one substituent selected from halo, -CN, C_1-C_6 alkyl, fluoro-(C_1-C_6)-alkyl, C_3-C_7 cycloalkyl and C_1-C_6 alkoxy;

each R^5 is independently either H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl, or, when two such groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent ~~azetidinyl, pyrrolidinyl,~~ piperidinyl, ~~homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl,~~ said ~~azetidinyl, pyrrolidinyl,~~ piperidinyl~~, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl~~ being optionally substituted by C_1-C_6 alkyl or C_3-C_7 cycloalkyl ~~and said piperazinyl and homopiperazinyl being optionally substituted on the nitrogen atom not taken together with the two R^5 groups to form the ring by -COR^7 or -SO_2R^7~~;

R^6 is a four to six-membered, aromatic, partially unsaturated or saturated non-heterocyclic group ~~containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s)~~, said non-heterocyclic group being optionally substituted by -OR^5, -NR^5R^5, -CN, oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, -COR^7 or halo;

R^7 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl;

R^8 is C_1-C_6 alkyl substituted by phenyl, pyridyl or pyrimidinyl, said phenyl, pyridyl and pyrimidinyl being optionally substituted by halo, -CN, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^7$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro-(C_1-C_6)-alkyl, C_3-C_7 cycloalkyl or C_1-C_6 alkoxy;

R^9 is H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl, said C_1-C_6 alkyl and C_3-C_7 cycloalkyl being optionally substituted by $-OR^5$, $-NR^5R^5$, $-NR^5COR^5$, $-CONR^5R^5$ or R^6;

R^{10} is (a) benzyl or C-linked R^6, said benzyl being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6, or (b) when R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), R^{10} is phenyl, C_1-C_6 alkyl or C_3-C_7 cycloalkyl each being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6;

X is $-CH_2-$, $-CHR^{11}-$, -CO-, -S-, -SO- or $-SO_2-$;

R^{11} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl or C_1-C_6 alkoxy; and

R^{12} is C_1-C_6 alkyl substituted by R^6, $-OR^5$, $-CONR^5R^5$, $-NR^5COR^5$ or $-NR^5R^5$.

154. (Withdrawn) The method according to claim 153 wherein R^1 is C_1-C_6 alkyl, $-OR^7$, $-CO_2R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^5CO$-(C_1-C_6 alkylene)-OR^5 or R^6, said C_1-C_6 alkyl being optionally substituted by halo, -CN, $-OR^5$, $-OR^8$, $-CO_2R^5$, $-CONR^5R^5$, $-OCONR^5R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^8R^9$, $-NR^5COR^5$, $-NR^5COR^6$, $-NR^5COR^8$, $-SO_2NR^5R^5$, $-NR^5CONR^5R^5$, $-NR^5SO_2R^7$ or R^6.

155. (Withdrawn) The method according to claim 154 wherein R^1 is C_1-C_6 alkyl, $-OR^7$, $-CO_2R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^5CO$-(C_1-C_6 alkylene)-OR^5 or R^6, said C_1-C_6 alkyl being optionally substituted by halo or $-OR^5$.

156. (Withdrawn) The method according to claim 155 wherein R^1 is C_1-C_3 alkyl, -OCH_3, -CO_2(C_1-C_2 alkyl), -$NHCO_2$(C_1-C_2 alkyl), -NH_2, -$N(CH_3)_2$, -$NHCOCH_2OCH_3$ or furanyl, said C_1-C_3 alkyl being optionally substituted by fluoro or -OH.

157. (Withdrawn) The method according to claim 156 wherein R^1 is methyl, ethyl, prop-2-yl, hydroxymethyl, trifluoromethyl, -OCH_3, -$CO_2CH_2CH_3$, -$NHCO_2CH_2CH_3$, -NH_2, -$N(CH_3)_2$, -$NHCOCH_2OCH_3$ or furan-2-yl.

158. (Withdrawn) The method according to claim 157 wherein R^1 is ethyl.

159. (Withdrawn) The method according to claim 153 wherein R^1 is methyl, ethyl, trifluoromethyl or -CH_2NHCH_2(4-cyanophenyl).

160. (Withdrawn) The method according to claim 153 wherein R^2 is H, C_1-C_6 alkyl, -(C_1-C_3 alkylene)-NR^5CO-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5CO-(phenyl), -(C_1-C_3 alkylene)-NR^5SO_2(C-linked R^6), -(C_1-C_3 alkylene)-NR^5CO(C-linked R^6), -(C_1-C_3 alkylene)-NR^5CO-(phenyl), each C_1-C_6 alkyl and phenyl being optionally substituted by halo, -OR^5, -OR^{12}, -CN, -CO_2R^7, -$CONR^5R^5$, -$OCONR^5R^5$, -$C(=NR^5)NR^5OR^5$, -$CONR^5NR^5R^5$, -$OCONR^5CO_2R^7$, -NR^5R^5, -NR^5R^{12}, -NR^5COR^5, -$NR^5CO_2R^7$, -$NR^5CONR^5R^5$, -$NR^5COCONR^5R^5$, -$NR^5SO_2R^7$, -$SO_2NR^5R^5$ or R^6.

161. (Withdrawn) The method according to claim 160 wherein R^2 is H, C_1-C_6 alkyl, -(C_1-C_3 alkylene)-NR^5CO-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5-(C_1-C_6 alkyl), -(C_1-C_3 alkylene)-NR^5CONR^5CO-(phenyl), -(C_1-C_3 alkylene)-$NR^5SO_2R^6$, -(C_1-C_3 alkylene)-NR^5COR^6, -(C_1-C_3 alkylene)-NR^5CO-(phenyl), each C_1-C_6 alkyl and phenyl being optionally substituted by halo, -OR^5, -CN, -CO_2R^7, -$CONR^5R^5$, -$OCONR^5R^5$, -$OCONR^5CO_2R^7$, -NR^5R^5, -$NR^5CONR^5R^5$, -$NR^5COCONR^5R^5$ or R^6.

162. (Withdrawn) The method according to claim 161 wherein R^2 is H, C_1-C_3 alkyl, -(C_1-C_2 alkylene)-NHCO-(C_1-C_3 alkyl), -(C_1-C_2 alkylene)-NHCONH-(C_1-C_3 alkyl), -(C_1-C_2 alkylene)-NHCONHCO-(phenyl), -(C_1-C_2 alkylene)-$NHSO_2R^6$, -(C_1-C_2 alkylene)-$NHCOR^6$, -(C_1-C_2 alkylene)-NHCO-(phenyl), each C_1-C_3 alkyl and phenyl being optionally substituted by fluoro, -OH, -O(C_1-C_6 alkyl), -CN, -CO_2(C_1-C_6 alkyl), -$CONH_2$, -$OCONH_2$, -$OCONHCO_2Ph$, -NH_2, -N(C_1-C_6 alkyl)$_2$, -$NHCONH_2$, -$NHCOCONH_2$ or R^6.

163. (Withdrawn) The method according to claim 161 wherein R^6 is 2,4-dihydroxypyrimidinyl, 1-methylimidazolyl, tetrahydrofuranyl, 1,5-dimethylpyrazolyl, tetrazolyl, pyridinyl, pyrimidinyl, 3-hydroxypyridazinyl, 2-hydroxypyridinyl, 2-oxo-2H-pyranyl or 1,2,3-thiadiazolyl.

164. (Withdrawn) The method according to claim 162 wherein R^2 is H, -CH_2OH, -CH_2CH_2OH, -$CH_2CH_2CH_2OH$, -CH_2OCONH_2, -$CH_2CH_2OCONH_2$, -$CH_2OCONHCO_2Ph$, -$CH_2CO_2CH_2CH_3$, -$CH_2CH_2CO_2CH_3$, -$CH_2CH_2CO_2CH_2CH_3$, -$CH_2CH_2CONH_2$, -$CH_2CH_2NH_2$, -$CH_2CH_2CH_2NH_2$, -$CH_2CH_2NHCOCHF_2$, -$CH_2CH_2NHCOCH_2CN$, -$CH_2CH_2NHCOCH_2N(CH_3)_2$, -$CH_2CH_2NHCOCH_2OCH_3$, -$CH_2CH_2NHCOCH_2OH$, -$CH_2CH_2NHCOCH_2OCH_2CH_3$, -$CH_2CH_2NHCOCH_2NHCONH_2$, -$CH_2CH_2NHCOCONH_2$, -$CH_2CH_2NHCONHCH_2CH_2CH_3$, -$CH_2CH_2NHCONHCOPh$, -$CH_2CH_2NHCONHCO$(2,6-difluorophenyl), -$CH_2CH_2NHSO_2$(2,4-dihydroxypyrimidin-5-yl), -$CH_2CH_2NHSO_2$(1-methylimidazol-4-yl), -CH_2CH_2NHCO(tetrahydrofuran-2-yl), -CH_2CH_2NHCO(1,5-dimethylpyrazol-3-yl), -$CH_2CH_2NHCOCH_2$(tetrazol-1-yl), -$CH_2CH_2NHCOPh$, -CH_2CH_2NHCO(pyridin-2-yl), -CH_2CH_2NHCO(pyrimidin-2-yl), -CH_2CH_2NHCO(2-fluorophenyl), -CH_2CH_2NHCO(3-hydroxyphenyl), -CH_2CH_2NHCO(3-hydroxypyridazin-6-yl), -CH_2CH_2NHCO(2-hydroxypyridin-6-yl), -CH_2CH_2NHCO(2-oxo-2H-pyran-5-yl) or -CH_2CH_2NHCO(1,2,3-thiadiazol-4-yl).

165. (Withdrawn) The method according to claim 153 wherein R^2 is H, methyl, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$, $-CH_2CH_2NH_2$, $-CH_2CH_2CH_2NH_2$, $-CH_2CN$, $-CH_2CH_2OCH_3$, $-CH_2CONH_2$, $-CH_2CH_2NHCOCH_2OCH_3$ or azetidin-3-yl.

166. (Withdrawn) The method according to claim 165 wherein R^2 is $-CH_2CH_2OH$, $-CH_2CH_2NH_2$, $-CH_2CN$ or azetidin-3-yl.

167. (Withdrawn) The method according to claim 153 wherein R^3 is C_1-C_6 alkyl, $-CO_2R^5$, $-CONR^5R^5$, $-NR^5CO_2R^7$ or $-NR^5R^5$, said C_1-C_6 alkyl being optionally substituted by halo, -CN, $-OR^5$, $-CO_2R^5$, $-CONR^5R^5$, $-OCONR^5R^5$, $-NR^5CO_2R^7$, $-NR^5R^5$, $-NR^5COR^5$, $-SO_2NR^5R^5$, $-NR^5CONR^5R^5$, $-NR^5SO_2R^7$ or R^6.

168. (Withdrawn) The method according to claim 167 wherein R^3 is C_1-C_6 alkyl, $-CO_2R^5$, $-CONR^5R^5$, $-NR^5CO_2R^7$ or $-NR^5R^5$, said C_1-C_6 alkyl being optionally substituted by halo, CN or $-OR^5$.

169. (Withdrawn) The method according to claim 168 wherein R^3 is C_1-C_3 alkyl, $-CO_2(C_1$-C_2 alkyl), $-CONH_2$, $-NHCO_2(C_1$-C_4 alkyl), $-N(CH_3)_2$ or $-NH_2$, said C_1-C_3 alkyl being optionally substituted by halo, -CN or -OH.

170. (Withdrawn) The method according to claim 169 wherein R^3 is methyl, ethyl, prop-2-yl, hydroxymethyl, cyanomethyl, trifluoromethyl, $-CO_2CH_2CH_3$, $-CONH_2$, $-NHCO_2C(CH_3)_3$, $-N(CH_3)_2$ or $-NH_2$.

171. (Withdrawn) The method according to claim 170 wherein R^3 is methyl, ethyl, prop-2-yl or trifluoromethyl.

172. (Withdrawn) The method according to claim 171 wherein R^3 is ethyl.

173. (Withdrawn) The method according to claim 153 wherein R^4 is 3,5-dichlorophenyl.

174. (Withdrawn) The method according to claim 153 wherein X is $-CH_2-$, $-CHR^{11}-$, -CO-, -S- or $-SO_2-$.

175. (Withdrawn) The method according to claim 174 wherein X is $-CH_2-$, $-CH(OCH_3)-$, -CO-, -S- or $-SO_2-$.

176. (Withdrawn) The method according to claim 175 wherein X is $-CH_2-$ or -S-.

177. (Withdrawn) The method according to claim 153 wherein the compound of formula Ib is selected from the group consisting of:

2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-isopropyl-3-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]acetate;

N^1-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}ethanediamide;

2-[(aminocarbonyl)amino]-*N*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}acetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-ethoxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-methoxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-3-hydroxybenzamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-hydroxyacetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-(dimethylamino)acetamide;

2-cyano-*N*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}acetamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2-fluorobenzamide;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-*N'*-propylurea;

N-benzoyl-*N'*-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}urea;

2-[4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazol-1-yl]acetate;

ethyl [4-(3,5-dichlorobenzyl)-5-isopropyl-3-methyl-1*H*-pyrazol-1-yl]acetate;

4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazole;

2-[4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

4-(3,5-dichlorobenzyl)-3-isopropyl-5-methyl-1*H*-pyrazole;

2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol;

2-{4-[(3,5-dichlorophenyl)sulfonyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol;

4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazole;

2-[4-(3,5-dichlorobenzyl)-3,5-dimethyl-1*H*-pyrazol-1-yl]ethanamine;

2-[4-(3,5-dichlorobenzyl)-5-ethyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-ethyl-5-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-ethyl-3-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-ethyl-5-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-3-(dimethylamino)-5-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-methoxy-3-methyl-1*H*-pyrazol-1-yl]ethanol;

2-[4-(3,5-dichlorobenzyl)-5-(2-furyl)-3-methyl-1*H*-pyrazol-1-yl]ethanol;

(3,5-dichlorophenyl)[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]methanone;

(±)-2-{4-[(3,5-dichlorophenyl)(methoxy)methyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol;

2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl carbamate;

methyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanoate;

ethyl 3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanoate;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]propanamide;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]-1-propanol;

[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]methanol;

[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]methyl carbamate;

2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethanamine;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}benzamide;

2-[4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-3-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol;

3-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]-1-propanamine;

2-[4-[(3,5-dichlorophenyl)sulfanyl]-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol;

N-{2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1*H*-pyrazol-1-yl]ethyl}-2,2-difluoroacetamide;

ethyl 4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1*H*-pyrazole-3-carboxylate;

[4-[(3,5-dichlorophenyl)sulfanyl]-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-3-yl]acetonitrile;

[4-[(3,5-dichlorophenyl)sulfonyl]-5-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-3-yl]acetonitrile;

2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol;

4-(3,5-dichlorobenzyl)-3-ethyl-1*H*-pyrazol-5-amine;

ethyl 4-(3,5-dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-5-ylcarbamate;

N-[4-(3,5-dichlorobenzyl)-3-ethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-5-yl]-2-methoxyacetamide;

2-[4-(3,5-dichlorobenzyl)-5-(dimethylamino)-3-ethyl-1*H*-pyrazol-1-yl]ethanol;

ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-5-methyl-1*H*-pyrazole-3-carboxylate;

ethyl 4-(3,5-dichlorobenzyl)-1-(2-hydroxyethyl)-3-methyl-1*H*-pyrazole-5-carboxylate;

2-[3-amino-4-(3,5-dichlorobenzyl)-5-methyl-1*H*-pyrazol-1-yl]ethanol;

ethyl [4-(3,5-dichlorobenzyl)-5-methoxy-3-methyl-1*H*-pyrazol-1-yl]acetate;

2-[5-amino-4-(3,5-dichlorobenzyl)-3-ethyl-1*H*-pyrazol-1-yl]ethanol;

and the pharmaceutically acceptable salts and solvates thereof.

178. (Withdrawn) The method of claim 177, wherein said compound is selected from the group consisting of:

2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-dimethyl-1*H*-pyrazol-1-yl}ethanol;
2-[4-[(3,5-dichlorophenyl)sulfanyl]-3-ethyl-5-(hydroxymethyl)-1*H*-pyrazol-1-yl]ethanol; and
2-{4-[(3,5-dichlorophenyl)sulfanyl]-3,5-diethyl-1*H*-pyrazol-1-yl}ethanol.

179. (Withdrawn) A method for the treatment of a disorder treatable by the inhibition of reverse transcriptase, comprising the administration of an effective amount of a compound of the formula Ib



(Ib)

or a pharmaceutically acceptable salt or solvate thereof, wherein

either (i) R^1 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, halo, -CN, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -NR^5CO-(C_1-C_6 alkylene)-OR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -OR^8, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^8R^9, -NR^5COR^5, -NR^5COR^6, -NR^5COR^8, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6 and

R^2 is -Y-Z,

or, R^1 and R^2, when taken together, represent unbranched C_3-C_4 alkylene, optionally wherein one methylene group of said C_3-C_4 alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being optionally substituted by R^5 or R^8,

and R^3 is H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl, benzyl, -CN, halo, -OR^7, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6, said C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl and benzyl being optionally substituted by halo, -CN, -OR^5, -CO_2R^5, -$CONR^5R^5$, -$OCONR^5R^5$, -$NR^5CO_2R^7$, -NR^5R^5, -NR^5COR^5, -$SO_2NR^5R^5$, -$NR^5CONR^5R^5$, -$NR^5SO_2R^7$ or R^6,

or (ii) R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), and R^2 is H,

provided that

(a) for definition (i), R^1 and R^3 are not both H,

(b) for definition (i), R^1 and R^3 are not both optionally substituted phenyl, as defined therein,

(c) for definition (i), when R^1 and R^3 are both methyl, R^2 is not phenyl or methyl, and

(d) for definition (ii), R^1 and R^3 are not both methyl;

Y is a direct bond or [[C_1-C_3]] C_1-C_6 alkylene;

Z is R^{10} or, where Y is C_1-C_3 alkylene, Z is $-NR^5COR^{10}$, $-NR^5CONR^5R^{10}$, $-NR^5CONR^5COR^{10}$ or $-NR^5SO_2R^{10}$;

R^4 is phenyl or pyridyl, each substituted by at least one substituent selected from halo, -CN, C_1-C_6 alkyl, fluoro-(C_1-C_6)-alkyl, C_3-C_7 cycloalkyl and C_1-C_6 alkoxy;

each R^5 is independently either H, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl, or, when two such groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent ~~azetidinyl, pyrrolidinyl,~~ piperidinyl, ~~homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl,~~ said ~~azetidinyl, pyrrolidinyl,~~ piperidinyl~~, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl~~ being optionally substituted by C_1-C_6 alkyl or C_3-C_7 cycloalkyl ~~and said piperazinyl and homopiperazinyl being optionally substituted on the nitrogen atom not taken together with the two R^5 groups to form the ring by $-COR^7$ or $-SO_2R^7$~~;

R^6 is a four to six-membered, aromatic, partially unsaturated or saturated non-heterocyclic group ~~containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s)~~, said non-heterocyclic group being optionally substituted by $-OR^5$, $-NR^5R^5$, -CN, oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, $-COR^7$ or halo;

R^7 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl, phenyl or benzyl;

R^8 is C_1-C_6 alkyl substituted by phenyl, pyridyl or pyrimidinyl, said phenyl, pyridyl and pyrimidinyl being optionally substituted by halo, -CN, $-CONR^5R^5$, $-SO_2NR^5R^5$, $-NR^5SO_2R^7$, $-NR^5R^5$, -(C_1-C_6 alkylene)-NR^5R^5, C_1-C_6 alkyl, fluoro-(C_1-C_6)-alkyl, C_3-C_7 cycloalkyl or C_1-C_6 alkoxy;

R^9 is H, C_1-C_6 alkyl or C_3-C_7 cycloalkyl, said C_1-C_6 alkyl and C_3-C_7 cycloalkyl being optionally substituted by $-OR^5$, $-NR^5R^5$, $-NR^5COR^5$, $-CONR^5R^5$ or R^6;

R^{10} is (a) benzyl or C-linked R^6, said benzyl being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6, or (b) when R^1 and R^3 are each independently C_1-C_6 alkyl, C_3-C_7 cycloalkyl or halo-(C_1-C_6 alkyl), R^{10} is phenyl, C_1-C_6 alkyl or C_3-C_7 cycloalkyl each being optionally substituted by halo, $-OR^5$, $-OR^{12}$, -CN, $-CO_2R^7$, $-CONR^5R^5$, $-OCONR^5R^5$, $-C(=NR^5)NR^5OR^5$, $-CONR^5NR^5R^5$, $-OCONR^5CO_2R^7$, $-NR^5R^5$, $-NR^5R^{12}$, $-NR^5COR^5$, $-NR^5CO_2R^7$, $-NR^5CONR^5R^5$, $-NR^5COCONR^5R^5$, $-NR^5SO_2R^7$, $-SO_2NR^5R^5$ or R^6;

X is $-CH_2$-, $-CHR^{11}$-, -CO-, -S-, -SO- or $-SO_2$-;

R^{11} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, fluoro-(C_1-C_6)-alkyl or C_1-C_6 alkoxy; and

R^{12} is C_1-C_6 alkyl substituted by R^6, $-OR^5$, $-CONR^5R^5$, $-NR^5COR^5$ or $-NR^5R^5$.